Carlos González Cáliz

Urologist (MD, FEBU). Uro-Oncology. Clinical research in Uro-Oncology. Passionate about advancing precision medicine and improving patient’s quality of life.

[Wall St Engine @wallstengine]

MODERNA, MERCK MRNA CANCER VACCINE SUCCEEDS IN PHASE 3

$MRNA and $MRK say their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial.

The study was stopped at its first interim analysis after positive results, though detailed efficacy data have not yet been released.

If the benefit holds up, this would mark the first randomized Phase 3 validation of a personalized neoantigen cancer vaccine and could significantly broaden the use of mRNA technology beyond traditional vaccines.

[The Wall Street Journal @WSJ]

An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validating decades of custom-treatment research https://t.co/nfhZF7xwq1

[Toni Kroos @ToniKroos]

Football won

[GUARD Consortium @GuardConsortium]

📖 LECTURA RECOMENDADA

El NCCN ha incorporado el testeo de ADN tumoral circulante (ctDNA) a sus guías de cáncer de vejiga, su tercera recomendación de categoría 1 sobre enfermedad mínima residual.

Un paso más hacia la monitorización molecular en la práctica clínica del cáncer de vejiga músculo-invasivo.

🔗 https://t.co/Pra5uEo1qu

#GUARDConsortium #GUOncology #CáncerDeVejiga #Oncología @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

[MJosé Juan @mjuanfi81]

🚨 Coincidence?
Within the same week,FDA approved:
🧬 Capivasertib+abiraterone for PTEN-deficient mHSPC(CAPItello-281)
🧬 Belzutifan+pembro for high-risk RCC (LITESPARK-022)
GU is moving beyond treating tumors by organ and increasingly toward treating them by biology @OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking new👉 today @US_FDA approved capivasertib (oral AKT inhibitor) for the metastatic HSPC/APMS #prostatecancer with PTEN deficiency👉personalized medicine continues to leap forward👉Capitello-281 ph3 trial summary👇 @OncoAlert @urotoday @AUC3_Official

[Papa León XIV @Pontifex_es]

Doy gracias a Dios y a todos los que me han acogido y que, de mil maneras, han colaborado en la preparación y la realización de los distintos momentos en Madrid, Barcelona, Montserrat y en las Islas Canarias. Regreso a Roma conmovido por el gran afecto con el que me han recibido, y reconfortado por los testimonios de fe y de amor a la Iglesia, expresiones del gran corazón católico de España.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper https://t.co/HmXyNvbExi 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

[pedro @pedromorillas68]

Más claro, imposible.

[Toni Choueiri, MD @DrChoueiri]

IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO

https://t.co/mbl2VKLZ2N

[Elena Castro @Ecastromarcos]

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer.
https://t.co/AhomCOFkZg

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟Molecular Diagnostics in mCRPC @Dolmos77

#PROSCA25 #GlobalForum25 @OncoAlert @mirrorsmed

🧬 Molecular diagnostics is no longer optional in mCRPC — it is the foundation of precision treatment. Key messages from David Olmos:

🔵 Tumour content matters: detection of SNVs, CNAs & biallelic loss depends entirely on % tumour and % ctDNA. Low purity = missed drivers.

🔵 ctDNA is powerful:
• Mutations >0.1%
• Monoallelic del >5–10%
• Biallelic del >20–30%

80% of mCRPC has measurable ctDNA → ideal for AR monitoring.

🔵 Somatic vs germline vs plasma:
• Somatic testing captures most actionable HRR alterations
• Germline must complement, not replace
• Plasma depends on tumour burden & CHIP interference

🔵 NGS technology matters: Hybrid capture >> amplicon for deletions & CNVs. Tissue failure drops <10% when pipelines are optimized.

🔵 CAPTURE study:
HRR mutations in 30.6%; BRCA1/2 13.2%. Parallel somatic + germline testing maximizes diagnostic yield.

🔵 VAF interpretation is essential:
VAF ≈50% → germline/LOH;
VAF > tumour purity → amplification/homozygous event.

💡 Take-home: Getting the right therapy starts with getting the molecular diagnosis right — the test, the sample, the tumour content, the platform, and the interpretation.

[David Henrie @DavidHenrie]

Sevilla… what a place.
Charming, alive, impossible to match. There’s a reason this city feels like the heart of Spain—because it is. This is the place that exported Spain to the New World, the image that comes to mind when we instinctively think “Spain.” Tile, color, devotion, courage, beauty… it all starts here.

What struck me most wasn’t just the architecture or the food (both insane), but the faith that built this city. A faith that actually led the world, nay, founded the very notice of human rights—yes, you read that right. Queen Isabel is known as the mother of human rights for a reason. History deserves honesty, and Sevilla deserves its rightful place in that story.

Also… my wife liked Sevilla better than Italy. Which breaks my Italian heart into a thousand little gelato-flavored pieces 😂🇮🇹💔

But hey—Sevilla earned it. We will be back. 

Till next time, España. 🇪🇸✨

[Daniel Castellano @cdanicas]

🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌
https://t.co/OFccsZ439w

👉.- The new molecular precision "triplet intensification" is here.
👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis.
👉.- We need to better biomarkers profile in this setting
@OncoAlert @APCCC_Lugano @ANZUPtrials @myESMO @GuardConsortium @fedelosco

[Carlos González Cáliz @CarlosGC88]

XI Reunión Andaluza Urología-Oncología Radioterápica #ProstateCancer

[UroToday.com @urotoday]

Matching adjusted indirect comparisons of TAR-200 vs FDA-approved novel agents in BCG-unresponsive high-risk #NMIBC with CIS. Presentation by @siadaneshmand @KeckMedicineUSC. #WSAUA25 written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/3THWn3qOl4 @auawest

[Adam B. Weiner, MD @Adam_Weiner535]

🚨23 years of PSA screening in @NEJM 🚨

👉ERSPC RCT of >162k patients

📅Median 23 year f/u PSA screening lead to...

📉 #prostatecancer mortality by 13%

✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa

📉Risk of advanced PCa by 34%

⭐️Benefit continues to rise over time as harm-benefit ratio improves

🔗https://t.co/hGCAfGpmhE

@PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc

[Oncology Brothers @OncBrothers]

GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies:

✅ #PSMAddition
✅ #CAPItello281
✅ #POTOMAC
✅ #Keynote905
✅ #IMvigor011

Full Discussion:
- https://t.co/4ZSNG39e6Q
- Also on the “Oncology Brothers” podcast

#OncTwitter #gusm @OncUpdates @myESMO

[Tom Powles @tompowles1]

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

[Alfonso Gómez de Liaño @Uro_Oncologist]

🧵#ESMO25 | CAPItello-281: First targeted therapy in PTEN-deficient mHSPC?
Capivasertib + abiraterone improved rPFS vs abiraterone in patients with de novo mHSPC and PTEN-deficient tumors (≥90% by IHC).
HR 0.81 (95% CI 0.66–0.98), p=0.034.
@Uromigos @urotoday @myESMO @OncoAlert